D. Boral Capital Reiterates “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX)

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating restated by D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $4.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 138.10% from the company’s current price.

Several other research firms have also recently issued reports on QNCX. Zacks Research raised shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Citigroup assumed coverage on shares of Quince Therapeutics in a research note on Tuesday, August 5th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quince Therapeutics in a research note on Wednesday, October 8th. Citizens Jmp started coverage on Quince Therapeutics in a report on Tuesday, August 5th. They issued a “strong-buy” rating and a $9.00 price target for the company. Finally, JMP Securities reduced their price target on Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Quince Therapeutics Stock Performance

Quince Therapeutics stock opened at $1.68 on Thursday. Quince Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $2.45. The company has a market capitalization of $93.54 million, a price-to-earnings ratio of -1.39 and a beta of 1.07. The stock has a fifty day moving average of $1.71 and a two-hundred day moving average of $1.53.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). On average, analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in shares of Quince Therapeutics during the 2nd quarter valued at $37,000. Virtu Financial LLC boosted its holdings in Quince Therapeutics by 48.4% in the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after acquiring an additional 14,128 shares during the last quarter. GSA Capital Partners LLP grew its position in Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after acquiring an additional 53,417 shares during the period. Bridgeway Capital Management LLC increased its stake in Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after acquiring an additional 22,200 shares during the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in shares of Quince Therapeutics in the 2nd quarter worth about $280,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.